See it. Treat it.
Using targeted radiation to combine imaging and therapy, Telix’s technology has the potential to change the way clinicians are able to find and treat cancer and rare diseases, to better inform treatment decisions and deliver truly personalised therapy for patients.
Molecularly targeted radiation (MTR)
Many existing cancer therapies are non-selective, impacting healthy tissue and vital organs at the same time as treating disease.
Existing external beam radiation therapy (EBRT) approaches are effective but typically only deliver localised treatment and also cause damage to surrounding tissue. Localised therapeutic approaches rely on the treating physician making assumptions about the extent of disease but missing even small amounts of surviving cells means the cancer or disease can recur over time.
MTR delivers targeted radiation to cancer cells with precision, regardless of where the cancer is in the body.